Trial Profile
A Non-interventional Study of the Safety of Pneumococcal 13-valent Conjugate Vaccine (Prevenar 13) in the Philippines: a Post Marketing Surveillance Study.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Feb 2017
Price :
$35
*
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Adverse reactions
- Sponsors Pfizer
- 13 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 25 Jul 2014 Planned End Date changed from 1 Jun 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov.
- 25 Jul 2014 Planned primary completion date changed from 1 Jun 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov.